The cannabis plant is comprised of, among other things, phytochemicals that have evolved over time to become very biologically active. Most of the current research and development (R&D) surrounding cannabis revolves around understanding these biologically-active ingredients, especially cannabinoids. To date, over 90 cannabinoids have been isolated from cannabis, each affecting the body’s cannabinoid receptors and responsible for distinctive pharmacological effects. The cannabinoids that bind more selectively to certain receptors have become more desirable for medical usage because of the advantage offered. Examples of phytochemicals that have been developed into pharmaceutical drugs include the bronchodilator (asthma), salicin (aspirin) and a number of cardiovascular agents.
InMed Pharmaceuticals is a Canadian drug discovery and development company with a unique focus on this area of cannabinoid science and the curative capabilities of cannabinoids. Since the 1980s, InMed has been developing a robust pipeline of therapies and products by leveraging its primary value drivers: its leadership team and its research and development into the extensive pharmacology of cannabinoids; its proprietary drug discovery platform; its proprietary cannabinoid manufacturing system; and its inventive drug delivery systems.
InMed benefits from the leadership of tested experts like Dr. Ado Muhammed, the company’s Chief Medical Officer. A proven leader in the field of cannabinoid therapies, Muhammed previously served as Associate Medical Director at GW Pharmaceuticals, a $3 billion cannabis biotechnology company. There, he played a strategic role in the delivery of core clinical research and key decision-making regarding R&D and product commercialization. Moreover, he was instrumental in leading that company through the development and regulatory approval of one of the first cannabis drugs in existence. InMed prides itself on being the only cannabis biotech company with a former GW Pharmaceuticals executive on board. This is a significant occurrence, as GW Pharmaceuticals is viewed as “the cannabis industry leader,” as well as a long-term biotech investment with a promising future. Since 2013, GW Pharmaceuticals’ shares have shot up from less than $9 to over $121 as of March 30, 2017, bringing it to a market value of approximately $2.9 billion.
Bioinformatics assessment is another of InMed’s core value drivers. As a general approach, this type of assessment opens up the world for future drug discovery, as it combines scores of data sets and builds holistic models to approach a specific disease. As part of its operations, InMed has created a computer-based program that assists in the discovery of novel cannabinoids using: (a) far-reaching algorithms to integrate data from various bioinformatics databases, (b) a database on the structure of currently-approved pharmaceutical products, and (c) a broad database containing the 90-plus individual cannabinoid drugs that have been found in cannabis. The company is now using this bioinformatics assessment tool to classify bioactive compounds within the cannabis plant that have the potential to have physiological impacts on specific diseases and to, ultimately, identify new drug candidates that heighten the therapeutic benefits of cannabis while restricting its adverse effects.
Biosynthesis — a process used in industrial applications, including the use of bacteria- or yeast-based systems for the production of pharmaceuticals — is also one of InMed’s primary value drivers. InMed is currently building up a high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. This process integrates the inbuilt safety and known effectiveness of natural drug structures with the convenience, control and quality of a laboratory-based manufacturing process. InMed’s proprietary approach to the production of pharmaceutical grade, bio-identical cannabinoids is a disruptive technology in the current and rapidly-emerging cannabinoid pharmaceutical sector.
Along with its proprietary in silico drug/disease bioinformatics assessment tool and its cannabinoid biosynthesis technology, InMed’s drug development pipeline is also a core asset. The company is leveraging a conservative clinical budget and accelerated drug development timelines to target unmet medical conditions using its disease-specific formulations. Presently, the company has two drug candidates in its pipeline:
- INM-750 is under pre-clinical development for the treatment of epidermolysis bullosa, an orphan pediatric disease that is typified by extremely fragile skin. Epidermolysis bullosa has no current approved therapies and represents an estimated $1 billion market.
- INM-085 is under pre-clinical development for the treatment of glaucoma, a severe eye disease with a global market of approximately $5.6 billion.
InMed Pharmaceuticals is also seeking and developing novel drug candidates for the treatment of conditions relating to dermatology, pain and inflammation, metabolic and respiratory diseases, and the ocular region and central nervous system.
For more information, visit the company’s website at www.InMedPharma.com
Let us hear your thoughts: InMed Pharmaceuticals, Inc. Message Board